Here's Why You Don't Bet Against This Dividend King - 24/7 Wall St. S&P 5006,437.70 +1.39% Dow Jones45,713.20 +0.99% Nasdaq 10023,324.80 +1.61% Russell 20002,453.53 +1.64% FTSE 10010,172.40 +0.90% Nikkei 22551,667.30 +1.25% Stock Market Live March 31, 2026: S&P 500 (SPY) Pops on News Trump Could End War Investing Here's Why You Don't Bet Against This Dividend King By Rich DupreyPublished Mar 31, 11:30AM EDT Quick Read Johnson & Johnson (JNJ) raised its quarterly dividend from $1.24 to $1.30 per share (5% ...

Core Viewpoint - Stryker Corp has reported a steady improvement in its manufacturing operations following a cyberattack that significantly disrupted its business activities. Group 1: Cyberattack Impact - A cyberattack on March 11 affected Stryker's operations, hindering order processing, manufacturing, and shipments [2]. - The attack was claimed by an Iran-linked hacking group called Handala, which stated it was retaliation for a strike on a girls' school in Minab, southern Iran [2]. - Devices running Microsoft's Windows operating system, including cellphones and laptops, were impacted by the attack [3]. Group 2: Recovery Efforts - Stryker has restored electronic ordering systems for customers and is working to reconcile orders, manufacture products, and deliver them as quickly and safely as possible [3]. - The company is coordinating with external cybersecurity experts and authorities to address the situation and has attempted to seize domains linked to the hackers [4]. Group 3: Market Reaction - Following the announcement of improved manufacturing capabilities, Stryker's shares climbed by 2% as most of its sites and critical lines were reported to be restored [2].

Summary of Key Points from the Conference Call on China's Silver Economy: Healthcare & Insurance Industry Overview - **Industry Focus**: The report centers on the healthcare and insurance sectors in China, particularly in the context of the aging population and the emerging "Silver Economy" [1][2][12]. Core Insights and Arguments - **Demographic Shift**: China is experiencing a rapid demographic transformation, with the population aged 65 and above expected to exceed 224 million by 2025, accounting for nearly 16% of the total population. This shift is significantly faster than in other major economies [12][13]. - **Healthcare Expenditure Growth**: Non-reimbursable healthcare expenditure is projected to grow from RMB 3.2 trillion in 2025 to RMB 6.5 trillion by 2035, reflecting a CAGR of 7.2%. This growth is driven by increased healthcare spending among older adults and the inadequacy of public healthcare funding [2][22]. - **Commercial Insurance Expansion**: The commercial insurance sector is expected to capture a larger share of healthcare expenditure, potentially covering 18% by 2035, up from 7% in 2024. This shift will add approximately RMB 2 trillion in funding to the healthcare system [28][29]. Key Beneficiaries - **Healthcare Sector**: - **Chronic Disease Management**: Online and offline chronic disease management services are crucial for elderly care delivery [3][40]. - **Innovative Pharma & Biotech**: Companies focusing on age-related disease treatments are positioned for growth, with innovative drug sales expected to grow at a CAGR of 15% by 2035 [4][29]. - **Advanced Medtech**: Firms providing solutions for physiological decline are also set to benefit [3][40]. - **Insurance Sector**: - **Commercial Long-Term Care Insurance (LTCI)**: The rollout of a nationwide LTCI system in 2026 presents significant opportunities for insurers, with premiums expected to grow at a CAGR of 12% from 2024 to 2030 [5][36]. Additional Important Insights - **Funding Gap**: The gap between total healthcare demand and public funding is widening, creating substantial market opportunities for commercial insurers and healthcare providers [21][25]. - **Health Literacy Increase**: The rise in health literacy among the elderly population is expected to drive demand for higher-quality healthcare services and innovative therapies [43]. - **Digital Health Ecosystem**: The integration of AI-driven platforms with traditional healthcare services is reshaping chronic disease management, enhancing patient engagement and care delivery [48][49]. Benefited Stocks - **Insurance Companies**: PICC P&C, China Life, CPIC are identified as key players in the insurance sector [6][36]. - **Healthcare Services**: Companies like Ali Health, Fangzhou, Gushengtang, and Aier Eye Hospital are positioned to benefit from the growing demand for healthcare services [6][40]. - **Pharma/Biotech**: Hengrui, Innovent, and Ribo are highlighted for their focus on innovative treatments for age-related diseases [6][40]. - **MedTech**: MicroPort is noted for its advancements in medical technology relevant to aging populations [6][40]. Conclusion - The aging population in China presents a multi-decade growth opportunity for both the healthcare and insurance sectors. The structural changes in demographics, coupled with increasing health awareness and technological advancements, are set to reshape the landscape of healthcare and insurance in the country [1][12][36].

Core Viewpoint - Stryker has contained a cyberattack that disrupted its operations, focusing on restoring systems that support customer orders and shipping [1][2]. Group 1: Cyberattack Details - The cyberattack occurred on March 11 and affected Stryker's order processing, manufacturing, and shipments [2]. - The attack was claimed by an Iran-linked hacking group named Handala, citing retaliation for a strike on a girls' school in Iran [2]. - Devices impacted included cellphones, laptops, and other remote devices running Microsoft's Windows operating system [3]. Group 2: Operational Impact - Stryker reported that no patient-related services or connected medical products were affected by the cyberattack [3]. - The company has not disclosed the financial impact of the attack [3]. Group 3: Response and Coordination - Stryker is coordinating with relevant authorities and external cybersecurity experts as part of its investigation into the incident [4]. - The company employs 56,000 staff and operates in 61 countries, indicating a significant global presence [4].

Core Viewpoint - Cardinal Health stock is currently in a buy zone, maintaining stability amid macroeconomic challenges such as the U.S.-Israeli war and drug pricing negotiations [1] Financial Performance - In the fiscal second quarter, Cardinal Health reported a 19% increase in pharmaceutical and specialty solutions sales, totaling $60.7 billion [1] - The global medical products and distribution unit generated $3.3 billion in sales, reflecting a 3% increase [1] - The "other" segment, which includes at-home solutions and nuclear/precision health solutions, saw a significant 34% year-over-year growth, generating $1.7 billion [1] Market Position and Analyst Sentiment - Cardinal Health is recognized as one of the top three medical wholesalers in the U.S., alongside McKesson and Cencora [1] - Analysts have given positive reviews, noting strong demand and effective execution across all business segments, with double-digit profit growth reported [1] - The company is expanding into specialty drugs and has made acquisitions to enhance its capabilities in this area [1] Stock Performance and Technical Indicators - Cardinal Health stock has a strong IBD Digital Relative Strength Rating of 91 out of 99, indicating robust performance compared to other stocks [1] - The stock has a Composite Rating of 94, placing it in the top 6% of all stocks across industries [1] - The stock remains above its 50-day and 200-day moving averages, indicating a favorable technical position [1]

Core Viewpoint - Stryker Corporation is experiencing significant disruptions to its business operations due to a cyberattack that affected its computer systems, impacting order processing, manufacturing, and shipping capabilities [1]. Group 1: Cyberattack Details - The cyberattack was claimed by an Iranian-linked hacking group named Handala, which stated the attack was in retaliation for a strike on a girls' school in Iran, resulting in an estimated 150 student fatalities according to Iranian officials [1]. - Stryker first reported the disruption on March 11, indicating a global impact on its Microsoft environment [1]. Group 2: Business Impact - The attack has led to widespread operational disruptions, but Stryker confirmed that patient-related services and connected medical products remain unaffected [1]. - The full scale and financial impact of the cyberattack are still under investigation by the company [1]. Group 3: Company Overview - Stryker employs approximately 56,000 individuals and operates in 61 countries worldwide [1].

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against monday.com Ltd. (NASDAQ: MNDY) on behalf of stockholders who purchased shares between September 17, 2025, and February 6, 2026, alleging that the company misled investors regarding its business operations and revenue growth outlook [1][1][1] Group 1: Allegations and Lawsuit Details - The lawsuit claims that monday.com Ltd. made false and/or misleading statements and concealed material adverse facts about its revenue expansion outlook, including decelerating growth, reduced expansion momentum, and extended sales cycles [1][1][1] - Investors are said to have suffered damages when the true state of the company's performance became known [1][1][1] Group 2: Participation and Representation - Shareholders wishing to serve as lead plaintiffs must file motions with the court by May 11, 2026, and do not need to participate in the case to be eligible for recovery [1][1][1] - All representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [1][1][1] Group 3: About Rosen Law Firm - Rosen Law Firm is recognized for its commitment to shareholder rights litigation, having recovered over $1 billion for shareholders since its inception [1][1][1] - The firm emphasizes its active role in litigating securities class actions, distinguishing itself from other firms that may not engage in such litigation [1][1][1]

Summary of JD Health International (6618.HK) Conference Call Company Overview - **Company**: JD Health International (6618.HK) - **Industry**: Healthcare Technology Key Financial Highlights - **2H25 Revenue**: Rmb38.2 billion, up 28% year-over-year (yoy), exceeding expectations by 5% compared to Goldman Sachs estimates and Visible Alpha Consensus Data [1] - **Non-IFRS Net Profit**: Rmb3 billion, a 38% yoy increase, beating estimates by 16% and 5% [1] - **Adjusted Net Profit Margin**: 7.8%, the highest margin for 2H in the company's history, with gross margin improving to 24.4%, up 0.8 percentage points from estimates [1] - **4Q25 Projections**: Revenue growth expected at 27% yoy and adjusted net profit growth at 30% yoy [1] Growth Drivers and Outlook - **Management Confidence**: Sustained growth momentum with FY26 revenue guidance of high-teens to 20% yoy, driven by strong drug and nutrition product sales, as well as advertising growth [2] - **Drug Sales Growth**: Expected to grow approximately 25% yoy in FY26, supported by original drugs and strong user mindshare [2] - **Nutrition Products**: Targeting around 15% yoy growth in FY26, benefiting from resource allocation and successful collaborations [2] - **Medical Devices**: Anticipated growth of about 10% yoy for FY26, reflecting steady industry growth [2] Margin and Profitability Insights - **Adjusted Operating Profit Margin**: Expected to remain at least flat yoy in FY26, benefiting from improved gross margins and advertising revenue growth [2] - **Investment in Technology**: Continuous improvement in gross margins is anticipated despite rising expenses due to investments in on-demand delivery and AI initiatives [2] Investment Rating and Price Target - **Rating**: Buy - **12-Month Target Price**: HK$75 per share, implying a 57.9% upside from the current price of HK$47.50 [3][9] Risks and Challenges - **Sales Growth Risks**: Potential for slower-than-expected sales growth in 2026, particularly in drug and non-drug categories [3][6] - **Margin Dynamics**: Concerns regarding margin dynamics due to ongoing investments in technology and competition from online pharmacies and e-commerce peers [6] Additional Financial Metrics - **Market Capitalization**: HK$151.5 billion / $19.4 billion [9] - **Revenue Forecasts**: Projected revenues for FY26 are Rmb83.1 billion, with EBITDA expected to reach Rmb4.1 billion [9] - **P/E Ratio**: Expected to be 19.1x in FY26 [9] Conclusion - JD Health International demonstrates strong financial performance with significant revenue and profit growth, driven by robust sales in drug and nutrition categories. The company maintains a positive outlook for FY26, although it faces potential risks related to sales growth and competitive pressures. The investment rating remains bullish with a substantial upside potential.

Core Insights - Boston Scientific reported fourth-quarter 2025 adjusted earnings per share of 80 cents, a 14.3% increase year-over-year, surpassing the Zacks Consensus Estimate by 2.6% and the company's guidance of 77-79 cents [2][3] - The company's total revenue for the fourth quarter reached $5.29 billion, reflecting a 15.9% year-over-year increase, exceeding the Zacks Consensus Estimate by 0.4% [4] Financial Performance - Adjusted earnings per share for the full year 2025 was $3.06, a 21.9% increase from 2024, also exceeding the Zacks Consensus Estimate by 0.7% [3] - The gross margin expanded by 172 basis points to 69.6%, while adjusted operating margin increased by 180 basis points to 24% [11] Revenue Breakdown - Fourth-quarter revenues by region showed a 17% increase in the United States, 12.4% in EMEA, 15.2% in Asia Pacific, and 15.9% in Latin America and Canada [6] - The MedSurg segment generated $1.81 billion in revenue, up 15.9% year-over-year, while the Cardiovascular segment reported $3.48 billion, an 18.2% increase [8][10] Future Outlook - For 2026, Boston Scientific anticipates net sales growth of approximately 10.5-11.5% on a reported basis, with adjusted earnings per share expected in the range of $3.43-$3.49 [12] - The first quarter of 2026 is projected to see revenue growth of approximately 10.5-12% on a reported basis, with adjusted earnings expected between 78-80 cents per share [13] Market Position - Boston Scientific holds a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the coming months [16] - The company has a Growth Score of B and a Momentum Score of C, placing it in the middle 20% for value investors [15]

Core Viewpoint - Robbins LLP has announced a class action lawsuit against Boston Scientific Corporation, alleging that the company misled investors regarding its projected revenue and growth potential during the specified class period [1]. Group 1: Allegations and Company Performance - The lawsuit claims that Boston Scientific created a false impression of having reliable information about its revenue outlook while downplaying risks from seasonality and macroeconomic factors [1]. - The company aimed to grow its share in the electrophysiology (EP) market at a rate of "2x the market," but faced new competition that negatively impacted its U.S. EP market share and growth potential [1]. - On February 4, 2026, Boston Scientific reported disappointing fourth quarter and full year 2025 results, particularly in U.S. EP sales, and provided guidance for fiscal 2026 that was significantly below expectations [1]. Group 2: Stock Price Impact - Following the announcement of disappointing results and guidance, Boston Scientific's stock price fell over 17%, dropping from $91.62 per share on February 3, 2026, to $75.50 per share on February 4, 2026 [1].